GlassScriptPhysician profile
Dean K Knudson
NPI 1215980008
$15,657.66
in general payments reported to CMS, 2019-2025
22 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $1,636 · 2021: $90.16 · 2022: $4,459 · 2023: $8,663 · 2024: $113 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,375 · Travel and Lodging: $1,893 · Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,375.00 |
| Travel and Lodging | $1,892.67 |
| Food and Beverage | $685.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,976.04 | 2021-2023 | |
| Allergan, INC. | $1,602.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $453.96 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $77.53 | 2023-2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $73.97 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.24 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $54.58 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $50.83 | 2020-2025 | Rexulti |
| Lundbeck LLC | $37.19 | 2019-2023 | Brintellix |
| Janssen Pharmaceuticals, INC | $36.11 | 2019-2025 | Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $35.46 | 2019-2021 | |
| Tempus Ai, INC | $27.74 | 2024 | |
| Neurocrine Biosciences, INC. | $23.69 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.40 | 2022 | |
| Almatica Pharma LLC | $19.34 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.34 | 2024 | Cobenfy |
| Jazz Pharmaceuticals INC. | $15.98 | 2019 | |
| Sage Therapeutics, LLC | $15.81 | 2025 | Zurzuvae |
| Bioxcel Therapeutics, INC. | $14.94 | 2023 | Igalmi |
| Tris Pharma INC | $14.86 | 2023 | Dyanavel Xr |
| Corium, LLC | $12.05 | 2024 | Azstarys |
| Neuronetics, INC. | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Knudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.